USANA (USNA) Insider Fleming Adds 1,058 Shares via RSU Vesting
Rhea-AI Filing Summary
USANA Health Sciences (USNA) Form 4: Director John Turman Fleming reported the automatic conversion of 1,058 Restricted Stock Units (RSUs) into an equal number of common shares on 24 Jul 2025 (transaction code M – derivative conversion). No cash price was paid at conversion.
Post-transaction holdings:
- Common stock held directly: 5,258 shares (up from 4,200).
- Unvested RSUs remaining: 3,172 units.
The RSU award vests in four equal tranches of 25% each on 24 Jul 2025, 23 Oct 2025, 22 Jan 2026 and 23 Apr 2026. Fleming’s filing reflects the first vesting event. There was no open-market buying or selling; the transaction simply moves shares from derivative to common ownership, marginally increasing the director’s freely tradable stake.
Given the modest size relative to USNA’s ~19 million outstanding shares, the event is immaterial to corporate finances. It does, however, signal continued equity alignment between the director and shareholders.
Positive
- Director increased direct share ownership by 1,058 shares, modestly aligning interests with shareholders.
Negative
- None.
Insights
TL;DR: Routine RSU vesting—small, neutral impact.
The filing records the scheduled vesting of 1,058 RSUs by director Fleming. Such conversions (code M) are pre-arranged and do not represent discretionary insider buying. Post-event, the director’s direct ownership rises to 5,258 shares, which is still <0.03 % of shares outstanding, so influence on float or insider-sentiment screens is negligible. No shares were sold, avoiding potential negative optics. Overall governance signal: neutral to mildly positive because equity incentives remain in place.
TL;DR: Non-cash, immaterial—no valuation effect.
From a market perspective, the RSU conversion neither injects cash nor dilutes shareholders, as the shares were already counted in fully diluted share count. The 1,058 shares equal roughly $58k at a $55 share price—insignificant against USNA’s $1 bn market cap. Trading volume impact is nil. Investors can treat this as housekeeping rather than a signal of upcoming corporate developments.